IMR Press / EJGO / Volume 25 / Issue 6 / pii/2004275

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

The use of erythropoietin in gynecologic cancer patients

Show Less
1 Department of Obstetrics and Gynecology of Patras University, Greece
Eur. J. Gynaecol. Oncol. 2004, 25(6), 735–736;
Published: 10 December 2004

Purpose: To investigate the possible benefits of erythroproietin ingestion in patients with various gynecological cancers with proven severe iron deficiency anemia. Method: Seven patients with gynecological cancer were included in the study. Nadir hematocrit values were found to be 20-24% before the initiation of recombinant human erythropoietin treatment. Initial therapy started at 50 µ/kg/dose, three times weekly for a month. The dose was modified according to the rise of hemoglobin after a month's period. The dose was modified according to the rise of hemoglobin after a month's period. If the rise was greater than 2 g/dl the dose was changed to 25 µ/kg two times weekly and if it was less than 2 g/dl it was changed to 25 µ/kg three times weekly per month. Five patients were simultaneously given ery­thropoietin therapy and iron supplementation. Results: We confirmed a rise in the hematocrit values which averaged 0.5-1.5% weekly till the upper limit. Reticulocyte and hema­tocrit values were higher in the erythropoietin plus iron group (five cases). Conclusion: In this small series, erythropoietin appeared to be effective in treating severe iron deficiency in gynecologic cancer patients. Further investigation is needed to confirm these results.

Gynecologic cancers
Severe anemia
Back to top